Search

CN

搜索
imgboxbg

Products

>
>
>
>
HemaSeq Human 74 Gene Mutation Detection Kit (NGS-for Illumina)
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part F_3504x2613
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part A_3504x2613
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part B_3504x2613
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part C_3504x2613
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part D_3504x2613
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part E_3504x2613
捕获法-全套_3700x2613

HemaSeq Human 74 Gene Mutation Detection Kit (NGS-for Illumina)

Product Introduction Targeted-capture NGS technology is applied to detect 74 core genes related to myeloid hematological tumors (MPN/AML/MDS/CMML) simultaneously. SNV, Indel and splicing can be obtained in the 74 core target regions all at once.
Cat. No.:
S0561-S
Spec:
6 rxns/Kit(60 Tests)
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part F_3504x2613
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part A_3504x2613
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part B_3504x2613
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part C_3504x2613
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part D_3504x2613
HemaSeq人类76基因突变检测试剂盒(可逆末端终止测序法)-Part E_3504x2613
捕获法-全套_3700x2613
Product description
Parameters

Detection Content

 

 

With NGS technology, mutations in 74 genes of myeloid hematological tumors can be detected at once, and the genes involved are related core genes for auxiliary diagnosis and differential diagnosis of hematological malignancies (see the gene list for details).

 

 

Advantages

 

1. Covers key genes in WHO, NCCN, ELN, Chinese guidelines for diagnosis and treatment of adult AML and authoritative literature to assist clinical decision-making.

2. Covers library preparation reagents, hybrid capture reagents, and probes for 74 genes in Kit  components.

3. Flexible with Illumina and ThermoFisher sequencing platforms.

4. High sensitivity, with accurate and stable detection of 1% mutation frequency.

 

 

 

 

Target Population

 

To address the actual clinical needs of myeloid hematological tumors, we have designed a 74-gene mutation detection panel based on the NCCN guidelines, WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (2008 and 2016 revision), expert consensus on hematological malignancies, authoritative classics, and the latest literature. Our panel is more suitable for clinical detection and has been developed in conjunction with nearly 20,000 accumulated cases from the Asian hematological driver mutation database. This panel is applicable to patients with suspected MDS, AML, CMML, MPN and other myeloid hematological tumors.

 

 

Gene List (only partial genes displayed)

 

 

ASXL1

EZH2

NRAS

GNAS

SETD2

SH2B3

BCOR

FLT3

PHF6

IKZF1

ATRX

ABL1

BCORL1

IDH1

PIGA

RAD21

KDM6A

STAT3

CALR

IDH2

PTPN11

ZRSR2

USH2A

JAK3

CBL

JAK2

RUNX1

PPM1D

MED12

DDX41

CEBPA

KIT

SETBP1

SMC1A

FBXW7

ANKRD26

CSF3R

KRAS

SF3B1

PTEN

PAX5

GATA2

DNMT3A

MPL

SRSF2

U2AF2

TP53

CUX1

ETV6

NF1

STAG2

ASXL2

U2AF1

GATA1

ETNK1

NPM1

TET2

ZBTB7A

WT1

NFE2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ordering Information

 

 

 

Cat. No.

Product

Strength

S0561-S

HemaSeq Human 74 Gene Mutation Detection Kit
(NGS-for Illumina)

6 rxns/Kit

(60 Tests)

 

Scan the QR code to read on your phone
We could not find any corresponding parameters, please add them to the properties table

Copyright:Wuhan Healthy Biotechnology Co., Ltd.